On September 16, 2021, leading experts from the SITC Immune Checkpoint Inhibitor-related Adverse Events Guideline Expert Panel presented the "SITC Clinical Practice Guideline Webinar – Practical Management Pearls for Immune Checkpoint Inhibitor-related Adverse Events." This high-level webinar...
2 attachments
On August 25, 2021, leading experts in cancer immunotherapy presented an overview of the publication "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer" during a live webinar. The recorded webinar and presentation...
On August 12, 2021, leading experts from the SITC Immune Effector Cell-related Adverse Events Guideline Expert Panel presented the "SITC Clinical Practice Guideline Webinar – Practical Management Pearls for Immune Effector Cell-related Adverse Events." This high-level webinar covered advanced...
On August 13, 2021, leading experts in cancer immunotherapy presented an overview of the publication "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events" during a live webinar. The recorded webinar and presentation...
Presentation slides and video from the 2020-2021 Advances in Cancer Immunotherapy ™ Series - Memphis, TN held virtually on March 20, 2021 are available here. Program Organizers Axel Grothey, MD – West Cancer Center & Research Institute Lee S. Schwartzberg, MD, FACP – West...
22 attachments
Presentation slides and video from the 2020-2021 Advances in Cancer Immunotherapy™ Series - Atlanta, GA held virtually on January 23, 2021 are available here. Program Organizers Caroline Claar, NP – Winship Cancer Institute of Emory University David H. Lawson, MD – Winship...
On March 5, 2021, leading experts in cancer immunotherapy presented an overview of the publication "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events" during a live webinar. The recorded webinar and presentation slides are...
The recent development and clinical implementation of novel immunotherapies for the treatment of Hodgkin and non-Hodgkin lymphoma have improved patient outcomes across subgroups. The rapid introduction of immunotherapeutic agents into the clinic, however, has presented significant questions...
FOR IMMEDIATE RELEASE Dec. 23, 2020 MILWAUKEE – The Society for Immunotherapy of Cancer (SITC) commends the global biomedical community for coming together to develop and authorize safe and effective SARS-CoV-2 vaccines at unprecedented speeds. SITC stands with the world in hoping that rapid...
Immune effector cell (IEC) therapies offer durable and sustained remissions in significant numbers of patients with hematological cancers. While these unique immunotherapies have improved outcomes for pediatric and adult patients in a number of disease states, as ‘living drugs,’ their toxicity...
Join
Renew
Member Directory
My Profile
Email Sign-up
Volunteer
Support SITC
Contact Us